Can Ozempic end addiction? | Dhruv Khullar | Your Body on Tech

Episode Summary

Executive Summary: The episode examines GLP-1 drugs like Ozempic as more than weight-loss or diabetes medications, highlighting emerging evidence that they may affect the brain, reduce cravings, and help treat addictions. Dr. Dhruv Kular urges cautious optimism: these drugs may expand treatment options and reshape stigma, but cost, side effects, access, and unknown long-term effects demand careful study and realistic expectations.

Main Topics: GLP-1s and addiction treatment (Priority: 5/5): Kular explains growing evidence that GLP-1 medications may reduce cravings and help people with alcohol, nicotine, opioid, and other behavioral addictions by moderating reward pathways in the brain. From gut hormone to brain effects (Priority: 5/5): The conversation traces GLP-1s from their origins as diabetes drugs to a broader neuroscience story, emphasizing uncertainty about exactly how they influence the brain and gut-brain signaling. Moderation as biology, not just morality (Priority: 4/5): The talk argues that self-control should be understood partly as a physiological state, challenging centuries-old moral framing of addiction and excess while still preserving some role for personal agency. Benefits beyond weight loss (Priority: 4/5): Kular notes reported and studied effects on cardiovascular health, stroke risk, fatty liver disease, chronic kidney disease, and osteoarthritis, suggesting GLP-1s may have wide medical utility. Risks, limits, and access barriers (Priority: 5/5): The episode balances enthusiasm with caution, discussing GI side effects, muscle loss, anhedonia, discontinuation rates, cost, and the risk of using these drugs without evidence for micro-dosing or cosmetic goals. Medicine, technology, and medical authority (Priority: 3/5): The discussion widens into how AI, online health culture, and direct-to-consumer medicine are changing the patient-physician relationship, making storytelling and evidence more important.

Key Arguments: GLP-1s may work on addiction by blunting reward-related dopamine spikes and easing withdrawal, not just by reducing appetite. Mary’s story suggests these drugs can create mental space for behavior change, helping people alter alcohol use, relationships, exercise, and diet. Addiction is deeply neurobiological, so stigma and shaming are ineffective and counterproductive. The mechanism is still not fully understood; researchers need careful trials before claiming broad efficacy. GLP-1s may be useful for many conditions beyond obesity, including heart, kidney, liver, inflammatory, and joint disease. These drugs are not a universal fix: adherence, side effects, cost, muscle loss, and possible emotional blunting limit real-world impact. Medical progress is unpredictable, which is why curiosity-driven research can lead to unexpected breakthroughs. Modern environments encourage excess and distraction, so moderation may require both biology-based tools and broader social change.

Data Points: People in the U.S. who have been on a GLP-1: 1 out of 8 - Kular cites this estimate while discussing how widespread the medications have become. Mary's weight loss: 55 pounds in 5 months - Described during the interview as a result of GLP-1 treatment, leading to medication discontinuation due to rapid loss. Mary's daily intake during treatment: 3, 4, 500 calories a day - Kular reports that Mary was eating only a few hundred calories per day while on the drug. FDA approval gap for alcohol use disorder medication: 20 years - He notes it has been two decades since the FDA last approved a medication for alcohol use disorder. Alcohol-related deaths since the turn of the century: More than doubled - Used to underscore the urgency of better addiction treatments. People who come off GLP-1s within a year: Half or more in some studies - Cited as a major limitation to effectiveness in the real world. Significant GI side effects in clinical trials: 5% to 10% - Kular says trial data suggest a minority stop due to GI issues, though real-world rates may be higher. Monthly sticker price: $1,000 to $1,300 - He identifies cost as a major barrier to access. First GLP-1 medication availability: 2005-2006 - He references exenatide as an earlier formulation that has provided some longer-term safety reassurance.

Pivotal Quotes: "I don't think they realize how much they affect their mind." — Mary: Her reflection after experiencing reduced alcohol cravings and broader life changes on a GLP-1. "GLP1s could be calming the water without draining the pool." — Dr. Dhruv Kular: Kular's metaphor for how the drugs may reduce reward spikes without eliminating all dopamine function. "I think that needs to be paired with an understanding that a lot of these processes are neurobiological, and shaming people because they have these conditions is not going to be a productive way to go about it." — Dr. Dhruv Kular: His argument against stigma as the appropriate response to addiction.

Implications: GLP-1s may reshape treatment for obesity, addiction, and chronic disease, but only if used with evidence, monitoring, and realistic expectations. They could also shift public thinking from moral blame toward neurobiology and moderation.